← All trials
NCT07149454
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 18, 2025
- Primary completion
- May 27, 2026
- Completion date
- Jun 24, 2026
- First posted
- Sep 2, 2025
- Last posted
- Sep 2, 2025
- Enrollment
- 68
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China National Biotec Group Co., LtdLead sponsor
- Shaanxi University of Chinese MedicineOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.